Search

Immunocore Holdings PLC ADR

Suletud

37.24 1.42

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

35.4

Max

36.79

Põhinäitajad

By Trading Economics

Sissetulek

-14M

-786K

Müük

9.3M

116M

Aktsiakasum

-0.02

Kasumimarginaal

-0.678

Töötajad

524

EBITDA

-13M

3.6M

Soovitused

By TipRanks

Soovitused

Osta

12 kuu keskmine prognoos

+70.36% upside

Dividendid

By Acuity

Järgmine tulemuste avaldamine

5. nov 2026

Turustatistika

By TradingEconomics

Turukapital

155M

1.8B

Eelmine avamishind

35.82

Eelmine sulgemishind

37.24

Immunocore Holdings PLC ADR Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

24. aug 2026, 20:06 UTC

Immunocore Holdings PLC shares are lower amid rising oil prices and geopolitical tensions, including new U.S. sanctions against Iran. No specific company news was identified.

21. aug 2026, 19:46 UTC

News

IMCR gains as JPMorgan reinstates coverage with Overweight rating.

20. aug 2026, 20:02 UTC

Immunocore Holdings PLC shares are lower today, reflecting declines in the Biotechnology sub-sector. The stock has shown notable volatility during the session.

19. aug 2026, 22:51 UTC

Immunocore Holdings PLC shares are higher in after-market hours, continuing an upward trend. No specific news was identified to explain the movement.

18. aug 2026, 20:01 UTC

Immunocore Holdings PLC is rising amid biotechnology sector strength, despite pulling back from an earlier session high. No specific company news was identified.

17. aug 2026, 19:23 UTC

News

Immunocore Holdings PLC shares are higher today following HC Wainwright's improved Q3 2026 earnings estimates, raising loss per share projections to -$0.08 from -$0.25.

14. aug 2026, 22:16 UTC

Immunocore Holdings PLC shares are lower in after-market trading. Broader market sentiment is impacted by declining retail sales and consumer confidence.

11. aug 2026, 20:01 UTC

Immunocore Holdings PLC is rising as biotechnology sector strength supports shares, though the stock has pulled back from an earlier session high.

10. aug 2026, 19:16 UTC

News

Immunocore Holdings PLC reports second-quarter revenue of $115.93 million, with shares lower amid broader market trends and declining U.S. stock futures.

7. aug 2026, 20:04 UTC

News

Immunocore Holdings reported a wider Q2 loss of 2 cents per share and $115.9 million in revenue, with shares trading lower since Thursday's close.

6. aug 2026, 19:52 UTC

News

Immunocore Holdings PLC reported Q2 earnings of -$0.02 per share and revenue of $115.93 million, exceeding expectations. Shares are trading higher during Thursday's session.

5. aug 2026, 20:02 UTC

Immunocore Holdings PLC is higher today, reflecting broader gains in the Biotechnology sector. No specific company news was identified to explain the movement.

4. aug 2026, 19:51 UTC

Immunocore Holdings PLC shares are higher today amid broader market strength and a notable decline in crude oil prices, easing inflation concerns.

3. aug 2026, 20:03 UTC

News

Immunocore Holdings PLC is declining in Monday's session, diverging from gains in major tech stocks and remaining below its 20-day moving average.

31. juuli 2026, 20:06 UTC

Immunocore Holdings PLC shares are lower today, with no specific news identified. The stock has fluctuated within a routine range during the session.

28. juuli 2026, 19:56 UTC

Immunocore Holdings PLC shares are lower today, continuing a three-session decline amid broader market sentiment influenced by declines in Asian markets.

27. juuli 2026, 18:06 UTC

Immunocore Holdings PLC shares are lower today, reflecting a broader market trend amid a significant decline in oil prices. No specific company news was identified.

24. juuli 2026, 15:26 UTC

Immunocore Holdings PLC shares are lower today, having declined from a session high. This movement occurs amid mixed labor market data and inflation concerns.

22. juuli 2026, 19:16 UTC

News

Immunocore Holdings PLC shares are higher as Wall Street Zen upgraded its rating to "buy," despite a mixed analyst outlook.

21. juuli 2026, 21:01 UTC

Immunocore Holdings PLC shares are higher in after-market trading, driven by optimistic sentiment in U.S. markets and better-than-expected results from major companies.

20. juuli 2026, 20:06 UTC

News

Immunocore Holdings PLC shares are lower amid broader market weakness. Analyst ratings show mixed sentiment, with upgrades and downgrades influencing performance.

Võrdlus sarnastega

Hinnamuutus

Immunocore Holdings PLC ADR Prognoos

Hinnasiht

By TipRanks

70.36% tõus

12 kuu keskmine prognoos

Keskmine 62.83 USD  70.36%

Kõrge 100 USD

Madal 35 USD

Põhineb 6 Wall Streeti analüütiku instrumendi Immunocore Holdings PLC ADR 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Osta

6 ratings

4

Osta

2

Hoia

0

Müü

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Immunocore Holdings PLC ADR

Immunocore Holdings plc, a commercial-stage biotechnology company, engages in the development of immunotherapies for the treatment of cancer, infectious, and autoimmune diseases. The company offers KIMMTRAK for the treatment of patients with unresectable or metastatic uveal melanoma. It also develops other programs for oncology, including tebentafusp that is in Phase 2/3 clinical trial to treat advanced cutaneous melanoma. In addition, the company's product pipeline comprises IMC-F106C, which is in a Phase 3 clinical trial to treat first line advanced cutaneous melanoma; and in a Phase 1/2 clinical trial in multiple tumor types, such as platinum resistant ovarian, non-small cell lung, and endometrial carcinoma. Further, it develops IMC-R117C, which is in phase 1 clinical trial to treat colorectal and gastrointestinal cancers; IMC-M113V, which is in phase 1 clinical trial to treat human immunosuppression virus; IMC-I109V, which is in a Phase I clinical trial in patients with chronic hepatitis B virus; IMC-T119C, which is in preclinical trial for multiple solid tumor cancers; IMC-P115C, which is in preclinical trial to treat multiple solid tumor cancers; and IMC-S118AI to treat type 1 diabetes and is in preclinical trial. Immunocore Holdings plc was founded in 1999 and is headquartered in Abingdon, the United Kingdom.
help-icon Live chat